Pemitinib 13.5 mg is identified as a product containing pemigatinib, an oral targeted anticancer medicine belonging to the fibroblast growth factor receptor (FGFR) inhibitor class. Pemigatinib works by blocking specific proteins involved in cellular signaling, growth and survival. It is designed for selected cancers associated with particular genetic abnormalities involving FGFR proteins.
Pemigatinib is an important medicine in precision oncology because certain cancers develop abnormal FGFR signaling that contributes to uncontrolled cell growth. By inhibiting selected FGFR proteins, pemigatinib can interfere with these abnormal signals and help manage cancers that depend on them.
The stated strength of Pemitinib featured on this website is 13.5 mg. The specific manufacturer, marketing authorization holder, packaging details and regulatory status of the Pemitinib-branded product must be established through its official product documentation.
Product Information | Details |
|---|---|
Product name | Pemitinib |
Generic medicine | Pemigatinib |
Stated strength | 13.5 mg |
Drug class | FGFR inhibitor |
Therapeutic category | Targeted anticancer medicine |
Dosage form | Oral tablet, subject to product verification |
Administration route | Oral |
Main molecular targets | FGFR1, FGFR2 and FGFR3 |
Reference brand | PEMAZYRE |
Reference product developer | Incyte |
Pemitinib manufacturer | Requires product-specific confirmation |
Pemigatinib is a small-molecule kinase inhibitor that selectively targets fibroblast growth factor receptors 1, 2 and 3.
Fibroblast growth factor receptors are proteins involved in important biological processes. They receive signals from fibroblast growth factors and transmit instructions into cells. These instructions influence cellular growth, development, differentiation, survival and the formation of blood vessels.
In certain cancers, genetic abnormalities involving FGFR proteins can cause these signaling pathways to become abnormally active. These changes may encourage cancer cells to grow and survive.
Pemigatinib blocks the kinase activity of selected FGFR proteins. This helps interfere with abnormal signaling and provides a targeted treatment approach for patients whose cancers have the relevant molecular alterations.
The medical uses described for pemigatinib include selected cases of FGFR2-altered cholangiocarcinoma and FGFR1-rearranged myeloid/lymphoid neoplasms, according to applicable regulatory labeling.
1. FGFR2-Altered Cholangiocarcinoma
Cholangiocarcinoma is a type of cancer that develops in the bile ducts. The bile ducts carry bile from the liver toward the digestive system.
Some cholangiocarcinomas contain genetic changes known as FGFR2 fusions or rearrangements. These abnormalities can activate signaling pathways that contribute to cancer growth.
Pemigatinib is used in selected adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma containing an eligible FGFR2 alteration.
Unresectable disease cannot be completely removed through surgery. Metastatic disease means that cancer has spread to other parts of the body.
Molecular testing is necessary to identify patients who may be eligible for this targeted treatment. Pemigatinib is not intended for every person diagnosed with cholangiocarcinoma.
2. FGFR1-Rearranged Myeloid/Lymphoid Neoplasms
Pemigatinib also has a U.S.-approved indication for adults with relapsed or refractory myeloid/lymphoid neoplasms containing an FGFR1 rearrangement.
These are uncommon blood-related cancers involving abnormal development and growth of blood-forming cells.
An FGFR1 rearrangement can produce abnormal signaling that contributes to disease progression. Pemigatinib targets this molecular abnormality by inhibiting FGFR1 activity.
This indication involves a different disease and treatment schedule from the cholangiocarcinoma indication.
Pemigatinib inhibits FGFR1, FGFR2 and FGFR3. These receptors are involved in signaling pathways that regulate cell growth and survival.
Under normal circumstances, FGFR signaling helps control cellular activities. However, certain genetic changes can make these pathways continuously active.
When this happens, abnormal signaling may support cancer-cell growth and survival.
Pemigatinib blocks the kinase activity of the relevant FGFR proteins, reducing signaling through these pathways.
This mechanism makes pemigatinib a targeted therapy rather than a conventional cytotoxic chemotherapy medicine.
Pemigatinib is administered orally according to the treatment schedule prescribed by an oncology specialist.
Under U.S. prescribing information for the reference product, the usual cholangiocarcinoma regimen is 13.5 mg once daily for 14 consecutive days, followed by seven days without treatment. Each treatment cycle lasts 21 days.
For eligible adults with relapsed or refractory FGFR1-rearranged myeloid/lymphoid neoplasms, the U.S. labeled regimen is 13.5 mg once daily on a continuous schedule.
These schedules are different and must not be confused.
General administration principles include:
Take the medicine exactly as prescribed.
Swallow the tablet whole.
Do not crush, chew, split or dissolve the tablet.
It may be taken with or without food.
Follow the prescribed treatment calendar.
Do not take an extra dose to compensate for vomiting or a missed dose.
Do not change the prescribed dose independently.
The appropriate dose and treatment schedule must be determined by a qualified healthcare professional.
Pemigatinib requires regular clinical and laboratory monitoring.
One important adverse reaction is hyperphosphatemia, which means an increased phosphate concentration in the blood. Pemigatinib can affect normal phosphate regulation, potentially leading to excessive phosphate levels.
High phosphate levels may contribute to calcium-phosphate deposition in soft tissues. Healthcare professionals may recommend dietary adjustments, phosphate-lowering treatment or dose modifications depending on laboratory findings and clinical circumstances.
Another important concern is ocular toxicity, particularly retinal pigment epithelial detachment (RPED). This condition affects the retina and can interfere with vision.
Patients should report blurred vision, visual floaters, flashes of light or other new visual disturbances promptly.
Other important precautions include monitoring for nail disorders, skin reactions, diarrhea, fatigue, nausea, dry eyes and mouth inflammation.
Possible adverse reactions associated with pemigatinib include:
Increased blood phosphate.
Hair loss.
Diarrhea.
Nail changes.
Fatigue.
Nausea.
Constipation.
Dry eyes.
Dry mouth.
Decreased appetite.
Vomiting.
Stomatitis.
Abdominal discomfort.
Dry skin.
Changes in taste.
Not every patient experiences these reactions. Their severity may vary depending on the treatment indication, dose and individual health factors.
PEMAZYRE is the established reference brand containing pemigatinib. Incyte is associated with the development of pemigatinib and the reference product.
However, the manufacturer of Pemitinib 13.5 mg should not automatically be identified as Incyte. The manufacturer of the specific Pemitinib product must be confirmed through its packaging and official pharmaceutical documentation.
Molecular testing is essential when considering pemigatinib for the relevant cancer indications.
For cholangiocarcinoma, testing must identify an FGFR2 fusion or qualifying rearrangement under the applicable prescribing requirements.
For myeloid/lymphoid neoplasms, an FGFR1 rearrangement is relevant to the U.S.-approved indication.
A general cancer diagnosis alone does not establish eligibility for pemigatinib treatment.
Pemitinib.com provides general educational information about pemigatinib and the Pemitinib product identified on this website.
This information does not replace professional medical advice, diagnosis, prescribing information or individualized treatment decisions.
Pemigatinib is a prescription anticancer medicine. Patients should not start treatment, discontinue therapy or change a prescribed dose without consulting their healthcare professional.
No posts found.
FGFR2 is a protein involved in cellular growth, development and signaling. Certain cholangiocarcinomas contain genetic changes, such as FGFR2 fusions or rearrangements, that can cause abnormal signaling and support cancer-cell growth. Identifying these changes through molecular testing can help specialists determine whether an FGFR inhibitor such as pemigatinib may be an appropriate treatment option.
An FGFR2 fusion or rearrangement is a genetic alteration in which the FGFR2 gene becomes abnormally connected to another genetic region or is otherwise structurally changed. These alterations may produce abnormal protein signaling that contributes to cancer development. A laboratory molecular test is needed to identify a qualifying alteration before treatment eligibility can be established.
A tissue biopsy is commonly used to establish a cancer diagnosis and may provide material for molecular testing. Depending on the clinical situation and available validated testing methods, a specialist may also consider other testing approaches. The important requirement is obtaining reliable evidence of the relevant genetic abnormality and confirming that the patient meets the applicable treatment criteria.
Pemigatinib has an established role in selected previously treated patients with unresectable locally advanced or metastatic cholangiocarcinoma containing an eligible FGFR2 fusion or rearrangement. Whether it is appropriate after chemotherapy or another cancer treatment depends on the patient's previous treatment history, current disease status, molecular findings and applicable prescribing guidance.
Increased phosphate levels, known as hyperphosphatemia, are an important effect of pemigatinib. The healthcare team may monitor blood phosphate levels, recommend dietary changes or phosphate-lowering treatment, and adjust or temporarily interrupt medication when clinically necessary. Patients should attend scheduled blood tests and should not attempt to manage abnormal phosphate levels without medical guidance.
Because pemigatinib can increase phosphate levels, the treating specialist or dietitian may recommend limiting certain foods that contain high amounts of phosphate. These can include some processed foods, products containing phosphate additives and selected dairy or protein-rich foods. Dietary recommendations should be based on laboratory results, nutritional needs and the patient's overall health rather than following a restrictive diet independently.
Yes. Nail disorders and skin-related reactions have been reported during pemigatinib treatment. Patients may notice nail changes, dryness, redness, irritation or other skin symptoms. The severity can vary. Report persistent, painful or worsening changes to the healthcare team so that appropriate supportive care and treatment adjustments can be considered.
Dry eyes and dry mouth have been reported in patients receiving pemigatinib. Patients should tell their healthcare professional if these symptoms become uncomfortable or persistent. The treating team can recommend suitable supportive measures and determine whether further assessment is needed. Eye discomfort accompanied by blurred vision or other visual changes requires prompt medical attention.
Retinal pigment epithelial detachment, or RPED, is an eye condition involving separation of layers in the retina. It is a recognized potential ocular complication of pemigatinib treatment. Eye examinations, including optical coherence tomography when recommended, help identify changes. New blurred vision, visual distortion, flashes or floaters should be reported to the treating specialist immediately.
Kidney and liver function are important considerations when prescribing pemigatinib. The patient's medical history and laboratory results should be reviewed before and during treatment. Severe renal or hepatic impairment may require a different starting dose under U.S. reference-product prescribing information. The treating specialist determines appropriate dosing and monitoring based on individual clinical circumstances.
Age alone does not automatically determine whether pemigatinib is suitable. Older adults may be considered for treatment when they meet the relevant clinical and molecular eligibility requirements. The specialist should assess overall health, kidney and liver function, other medicines, existing medical conditions and the patient's ability to undergo regular monitoring before recommending treatment.
The suitability of combining pemigatinib with other anticancer medicines depends on the diagnosis, treatment plan, clinical evidence and potential interactions. Its established labeled uses should not be assumed to include every possible combination. Patients should not combine pemigatinib with chemotherapy, targeted therapy or other prescription medicines unless the treating cancer specialist specifically recommends the combination.
Monitoring may include blood phosphate measurements, assessment of other laboratory results, review of adverse reactions and regular eye examinations. The healthcare team may also evaluate the cancer's response through appropriate clinical assessments and imaging. The exact monitoring schedule depends on the treatment indication, the patient's condition and the applicable prescribing information.
Patients should examine the product packaging, medicine name, active ingredient, strength, dosage form, batch number, expiry date and manufacturer details. They should also confirm the product's registration and supply information through appropriate official sources. A pharmacist or healthcare professional can help assess product documentation. The identity and regulatory status of a specific Pemitinib-branded product should not be assumed without verification.
Before treatment, patients should discuss their confirmed diagnosis, molecular test results, previous cancer treatments, current medicines, allergies and other medical conditions. They should also ask about the prescribed dosing schedule, phosphate monitoring, eye examinations, possible adverse effects, pregnancy precautions and symptoms that require urgent attention. These discussions help the specialist determine whether pemigatinib is appropriate and establish a safe monitoring plan.